Takeda Pharmaceutical (TAK) Net Income towards Common Stockholders (2017 - 2026)
Takeda Pharmaceutical's Net Income towards Common Stockholders was $710.19 million in the quarter ended Jun 30, 2026, down 17.3% from $858.66 million a year earlier and down 10.4% from the prior quarter.
Takeda Pharmaceutical (TAK) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
On a trailing twelve-month basis, Takeda Pharmaceutical's Net Income towards Common Stockholders was $3.64 billion through Jun 30, 2026, up 12.3% year-over-year; for the year ended Mar 31, 2026, it was -$1.01 billion.
- In earlier years, Net Income towards Common Stockholders was $708.53 million in the year ended Mar 31, 2025 (-29.1%), $998.98 million in the year ended Mar 31, 2024 (-57.4%), $2.35 billion in the year ended Mar 31, 2023 (+14.5%) and $2.05 billion in the year ended Mar 31, 2022 (-42.2%).
- Quarterly Net Income towards Common Stockholders has moved between $156.48 million (the quarter ended Dec 31, 2024) and $2.07 billion (the quarter ended Sep 30, 2022) over five years.
- Compared with a year earlier, Net Income towards Common Stockholders was higher in four of the last eight quarters, with growth averaging 34.3%.
- The best year-over-year quarter for Net Income towards Common Stockholders over five years was the quarter ended Dec 31, 2025 (growth of 330.4%); the worst was the quarter ended Dec 31, 2024 (a decline of 78.1%).
- Per Business Quant data, TAK's Net Income towards Common Stockholders in the three quarters before the quarter ended Jun 30, 2026 was $792.61 million (quarter ended Mar 31, 2026), $673.44 million (quarter ended Dec 31, 2025) and $1.47 billion (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Takeda Pharmaceutical | 2.58 Bn | -23.92 Bn | 5.10 Bn | 710.19 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 710.19 Mn |
| Mar 31, 2026 | 792.61 Mn |
| Dec 31, 2025 | 673.44 Mn |
| Sep 30, 2025 | 1.47 Bn |
| Jun 30, 2025 | 858.66 Mn |
| Mar 31, 2025 | 814.74 Mn |
| Dec 31, 2024 | 156.48 Mn |
| Sep 30, 2024 | 1.42 Bn |
| Jun 30, 2024 | 611.86 Mn |
| Mar 31, 2024 | 643.07 Mn |
| Dec 31, 2023 | 715.22 Mn |
| Sep 30, 2023 | 1.98 Bn |
| Jun 30, 2023 | 652.31 Mn |
| Mar 31, 2023 | 793.80 Mn |
| Dec 31, 2022 | 843.22 Mn |
| Sep 30, 2022 | 2.07 Bn |
| Jun 30, 2022 | 812.01 Mn |
| Mar 31, 2022 | 1.18 Bn |
| Jun 30, 2021 | 1.26 Bn |
| Mar 31, 2021 | 1.86 Bn |
Takeda Pharmaceutical Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=TAK&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "TAK", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=TAK&period=max&api_key=YOUR_API_KEY");
const data = await res.json();